Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in:

23.03.2020

Psychotropic polypharmacy and its association with health-related quality of life among cancer survivors in the USA: a population-level analysis

verfasst von: Ami Vyas, Ghadah Alghaith, Meghan Hufstader-Gabriel

Erschienen in: Quality of Life Research | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer survivors that use multiple psychotropic medications are at an increased risk of psychotropic polypharmacy. We examined the association between psychotropic polypharmacy and health-related quality of life (HRQoL) among cancer survivors living in the USA.

Methods

We used the Medical Expenditure Panel Survey (MEPS) data for 2010, 2012, and 2014 to identify adult cancer survivors. Psychotropic polypharmacy was defined as use of at least two classes of psychotropic prescription medications. The physical component summary (PCS) and the mental component summary (MCS) were obtained from the 12-item Short Form Health Survey version 2 to measure HRQoL. Adjusted ordinary least square regressions were performed to evaluate the association between psychotropic polypharmacy and HRQoL.

Results

Among 31 million US cancer survivors (weighted from a sample of 2609), 16.3% reported psychotropic polypharmacy. Lung cancer survivors had the highest prevalence of psychotropic polypharmacy (22.5%), followed by survivors of breast cancer (17.8%), colorectal, and other gastrointestinal cancers (16.0%). The unadjusted PCS and MCS scores for those with psychotropic polypharmacy were significantly lower than those without psychotropic polypharmacy, overall, and for each cancer type. In multivariable regressions, cancer survivors with psychotropic polypharmacy had significantly lower PCS scores (β =  − 3.63, p < 0.0001) and MCS scores (β =  − 2.28, p = 0.0138) compared to those without psychotropic polypharmacy.

Conclusion

Cancer survivors requiring multiple psychotropic medications have poorer quality of life.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Bluethmann, S. M., Mariotto, A. B., & Rowland, J. H. (2016). Anticipating the “Silver Tsunami”: Prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiology, Biomarkers & Prevention,25, 1029–1036.CrossRef
2.
Singer, S., Das-Munshi, J., & Brahler, E. (2010). Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis. Annals of Oncology,21, 925–930.CrossRef
3.
Mitchell, A. J., Chan, M., Bhatti, H., et al. (2011). Prevalence of depression, anxiety, and adjustment disorders in oncological, haematological, and palliative care settings: A meta-analysis of 94 interview-based studies. Lancet,12(2), 160–174.CrossRef
4.
Ng, C. G., Boks, M. P., Smeets, H. M., Zainal, N. Z., & de Wit, N. J. (2013). Prescription patterns for psychotropic drugs in cancer patients: A large population study in the Netherlands. Psychooncology,22(4), 762–767.CrossRef
5.
Farriols, C., Ferrandez, O., Planas, J., Ortiz, P., Mojal, S., & Ruiz, A. I. (2012). Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. Journal of Pain and Symptom Management,43(5), 945–952.CrossRef
6.
Punekar, R. S., Short, P. F., & Moran, J. R. (2012). Use of psychotropic medications by US cancer survivors. Psychooncology,21(11), 1237–1243.CrossRef
7.
Bruera, E., & Neumann, C. (1998). The uses of psychotropics in symptom management in advanced cancer. Psychooncology,7(4), 346–358.CrossRef
8.
Thekdi, S. M., Irarrazaval, M. E., & Dunn, L. B. (2012). Psychopharmacological interventions. In L. Grass & M. Riba (Eds.), Clinical psycho-oncology: An international perspective (pp. 109–126). Chichester: Willey-Blackwell.CrossRef
9.
Mojtabai, R., & Olfson, M. (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry,67(1), 26–36.CrossRef
10.
Correll, C. U., & Gallego, J. A. (2012). Antipsychotic polypharmacy: A comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatric Clinics of North America,35(3), 661–681.CrossRef
11.
Sandson, N. B., Armstrong, S. C., & Cozza, K. L. (2005). An overview of psychotropic drug-drug interactions. Psychosomatics,46(5), 464–494.CrossRef
12.
Yap, K. Y., Tay, W. L., Chui, W. K., & Chan, A. (2011). Clinically relevant drug interactions between anticancer drugs and psychotropic agents. European Journal of Cancer Care (England),20(1), 6–32.CrossRef
13.
Aroke, H., Vyas, A., Buchanan, A., & Kogut, S. (2019). Prevalence of psychotropic polypharmacy and associated healthcare utilization during initial phase of care among adults with cancer in USA. Drugs Real World Outcomes,6(2), 73–82.CrossRef
14.
Vyas, A., Kogut, S., & Aroke, H. (2019). Real-world direct healthcare costs associated with psychotropic polypharmacy among adults with common cancer types in the United States. Journal of Managed Care & Specialty Pharmacy,25(5), 555–565.CrossRef
15.
Harrison, S. L., Bradley, C., Milte, R., et al. (2018). Psychotropic medications in older people in residential care facilities and associations with quality of life: A cross-sectional study. BMC Geriatrics,18, 60.CrossRef
16.
Thompson Coon, J., Abbott, R., Rogers, M., et al. (2014). Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: A systematic review. Journal of the American Medical Directors Association,15(10), 706–718.CrossRef
17.
18.
19.
Ware, J., Jr., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care,34, 220–233.CrossRef
20.
Ware, J., Jr., Kosinski, M., Turner-Bowker, D. M., & Gandek, B. (2002). SF-12v2: How to score version 2 of the SF-12 health survey (with a supplement documenting version 1). Lincoln, RI: QualityMetric Inc.
21.
Braun, I. M., Rao, S. R., Meyer, F. L., & Fedele, G. (2015). Patterns of psychiatric medication use among nationally representative long-term cancer survivors and controls. Cancer,121, 132–138.CrossRef
22.
Jones, S. M., Rosenberg, D., Ludman, E., & Arterburn, D. (2015). Medical comorbidity and psychotropic medication fills in older adults with breast or prostate cancer. Supportive Care in Cancer,23(10), 3005–3009.CrossRef
23.
Bradley, S., Rose, S., Lutgendorf, S., Costanzo, E., & Anderson, B. (2006). Quality of life and mental health in cervical and endometrial cancer survivors. Gynecologic Oncology,100(3), 479–486.CrossRef
24.
Fleer, J., Hoekstra, H. J., Sleijfer, D. T., Tuinman, M. A., Klip, E. C., & Hoekstra-Weebers, J. E. (2006). Quality of life of testicular cancer survivors and the relationship with socio-demographics, cancer-related variables, and life events. Supportive Care in Cancer,14(3), 251–259.CrossRef
25.
Peuckmann, V., Ekholm, O., Rasmussen, N. K., et al. (2007). Health-related quality of life in long-term breast cancer survivors: Nationwide survey in Denmark. Breast Cancer Research and Treatment,104(1), 39–46.CrossRef
26.
Wang, S., Hsu, S. H., Gross, C. P., et al. (2016). Association between time since cancer diagnosis and health-related quality of life: A population-level analysis. Value Health,19, 631–638.CrossRef
27.
Hays, R. D., & Morales, L. S. (2001). The RAND-36 measure of health-related quality of life. Annals of Medicine,33, 350–357.CrossRef
28.
Paltiel, O., Marzec-Boguslawska, A., Soskolne, V., et al. (2004). Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life. Quality of Life Research,13(10), 1699–1706.CrossRef
29.
Stein, M. B., & Barrett-Connor, E. (2002). Quality of life in older adults receiving medications for anxiety, depression or insomnia: Findings from a community-based study. American Journal of Geriatric Psychiatry,10(5), 568–574.CrossRef
30.
Liavaag, A. H., Dorum, A., Fossa, S. D., Trope, C., & Dahl, A. A. (2009). Morbidity associated with ‘self-rated health’ in epithelial ovarian cancer survivors. BMC Cancer,9, 2.CrossRef
31.
Krebber, A. M., Jansen, F., Witte, B. I., et al. (2016). Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: A randomized, controlled trial. Annals of Oncology,27(9), 1754–1760.CrossRef
32.
Yabroff, K. R., Warren, J. L., Banthin, J., et al. (2009). Comparison of approaches for estimating prevalence costs of care for cancer patients: What is the impact of data source? Medical Care,47(7 Suppl 1), S64.CrossRef
33.
Ereshefsky, L., & Sloan, D. M. (2009). Drug–drug interactions with the use of psychotropic medications. CNS Spectrums,14(8), 1–8.PubMed
Metadaten
Titel
Psychotropic polypharmacy and its association with health-related quality of life among cancer survivors in the USA: a population-level analysis
verfasst von
Ami Vyas
Ghadah Alghaith
Meghan Hufstader-Gabriel
Publikationsdatum
23.03.2020
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 8/2020
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-020-02478-6

Weitere Artikel der Ausgabe 8/2020

Proxy reliability of the 12-item world health organization disability assessment schedule II among adult patients with mental disorders

The impact of metabolic syndrome on mental health-related quality of life and depressive symptoms

Role of depressive symptoms in the health-related quality of life of Venezuelan patients with rheumatoid arthritis. Results from a tertiary care center

Development of a patient-reported experience questionnaire for patients with sarcoma: the Sarcoma Assessment Measure (SAM)

Development and content validation of a questionnaire measuring patient empowerment in cancer follow-up

Minimal important change in physical function in trauma patients: a study using the short musculoskeletal function assessment

  • Open Access